Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included. Several samples from different tissues will be analyzed through different omics to establish predictive biomarkers of response to the treatment. Multiple algorithms will then be used to look for an integrative predictive algorithm that incorporates multi-parameter inputs in order to develop a clinical tool to assist clinicians in the process of treatment decision-making in TNBC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowotwór piersi potwierddzony badaniem mikroskopowym, ujemny w testach na HER2, receptory estrogenowe i progesteronowe
- •Zaawansowana rak piersi stadium 2-3 potwierdzona badaniami obrazowymi lub oceną lekarza
- •Pacjent może otrzymywać chemioterapię przed operacją, z immunoterapią lub bez niej
- •Wiek co najmniej 18 lat
✗ Disqualifies
- •Przerzuty raka do innych narządów (stadium 4) potwierdzone badaniem obrazowym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 23, 2023
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Trial contact
Mafalda Oliveira, MD PhD
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.